Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
Palvella Therapeutics announced the issuance of a U.S. patent licensed from Yale University that strengthens intellectual property protection for its QTORIN™ pitavastatin program targeting porokeratosis, including disseminated superficial actinic porokeratosis (DSAP). This patent provides broad protection into 2043 for topical mevalonate pathway in…
Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, announced filing a provisional patent application for a Coaxial Dual-Propellant Grain Solid Rocket Motor (CDPG-SRM). The technology aims to extend range and endurance for small unmanned aerial vehicles used in defense, border security, and autonomous warfare, addressing key …
TransUnion has been named one of America’s Most Trustworthy Companies for 2026 by Newsweek, highlighting its commitment to integrity, responsible data stewardship, and innovation in credit reporting, fraud prevention, and consumer solutions. The accolade underscores TransUnion's focus on accuracy, fairness, transparency, and its strategy toward sus…
Maze Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference in June 2026. The company highlighted its clinical-stage biopharmaceutical pipeline focused on kidney and metabolic diseases, including two Phase 2 drug candidates.
Invivyd, Inc., a U.S.-based biopharmaceutical company specializing in antibody treatments for viral infectious diseases, announced it will participate in several investor events in June 2026, including the Jefferies Global Healthcare Conference, H.C. Wainwright Virtual Fireside Chat, and BTIG Infectious Disease Day. The company highlights its propr…
Atea Pharmaceuticals announced Phase 1 data indicating their fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus (HCV) treatment displays a low risk of drug-drug interactions, supporting its use alongside common medications such as omeprazole and rosuvastatin. Additionally, preclinical results for AT-587, a …
Dycom Industries, Inc. reported record first quarter fiscal 2027 results with contract revenues of $1.965 billion, a 56.1% increase from the prior year, strong profitability, and a backlog growth of 46.5%. The company raised its full-year fiscal 2027 outlook and announced the acquisition of National Technology Integrators to enhance its Building Sy…
BrewDog, a leading UK craft beer brand owned by Tilray Brands, is launching a nationwide summer campaign called 'Underdog' to coincide with the global football tournament. The campaign includes a 'Win a Year of Beer' promotion across major UK retailers, in-bar football watch parties, themed events, and extensive digital and retail activations. This…
Satellos Bioscience Inc., a clinical-stage biotech focused on developing treatments for degenerative muscle diseases, will participate in upcoming investor conferences in June 2026. The company will present updates on its lead drug candidate, SAT-3247, currently in Phase II trials for Duchenne muscular dystrophy (DMD). SAT-3247 targets the AAK1 pro…
LeonaBio, a clinical-stage biopharmaceutical company, announced its participation in two major medical industry events in June 2026. The company will present details on its ALS drug candidate ATH-1105 at the 5th Annual ALS Drug Development Summit and participate in a panel on oncology trials at the BIO International Convention. These engagements un…
Harrow, Inc., a Nasdaq-listed company specializing in ophthalmic disease management, announced its management will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026. The presentation will highlight the company’s portfolio addressing eye diseases and will be webcast live with a replay available for 90 days.
Sagimet Biosciences announced the presentation of two posters at EASL 2026 showcasing Phase 1 clinical data on the combination of denifanstat and resmetirom for treatment of metabolic dysfunction-associated steatohepatitis (MASH). The combination was generally well-tolerated and demonstrated rapid reductions in total and LDL cholesterol, suggesting…
Aurora Mobile Limited announced major upgrades to its enterprise AI platform GPTBots.ai, enhancing its capabilities from conversational AI to active execution within business workflows. Key improvements include a knowledge graph-based understanding system, advanced multi-agent workflow execution, and strengthened governance for secure production de…
Balchem Corporation announced its participation in the Wells Fargo Industrials Conference on June 10, 2026, where key executives including the CEO, CFO, and Senior Director of Investor Relations will present. The company is a global specialty ingredient manufacturer serving health and nutrition markets with three main business segments: Human Nutri…
Rocket Lab USA, Inc. has successfully passed the System Requirements Review for the Space Development Agency's Tracking Layer Tranche 3 constellation, confirming their proposed solution meets operational requirements for missile warning and defense satellites. This milestone supports a contract valued at approximately $816 million, adding to Rocket…
Telix Pharmaceuticals Limited announced that Dr. Christian Behrenbruch, the company's Managing Director and Group CEO, will present at two major investor conferences in the United States: the William Blair 46th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference. These presentations aim to update investors on Telix's progr…
Climb Global Solutions, an international specialty technology distributor, announced a new North American distribution partnership with Quantum Corporation, a leader in data protection and management solutions. This partnership expands access to Quantum's product portfolio, helping resellers address complex data challenges with high-performance sto…
MediWound reported first quarter 2026 financial results, highlighting ongoing enrollment in the EscharEx Phase III VALUE study and expanding U.S. adoption of NexoBrid. The company reaffirmed full-year revenue guidance of $24-26 million despite a Q1 revenue decline due to timing of BARDA-related revenues and regional shipment delays. Increased R&D e…
G-III Apparel Group, Ltd., a global fashion leader with a diverse brand portfolio, declared a quarterly cash dividend of $0.10 per share payable to shareholders on July 8, 2026. The announcement reflects the company's ongoing commitment to returning value to investors amid its extensive licensing and retail operations in the fashion sector.
Intchains Group Limited, a Nasdaq-listed company specializing in altcoin mining and staking, announced its participation in the Noble Capital Markets Emerging Growth Virtual Equity Conference scheduled for June 3-4, 2026. The company will present its business strategy and engage with investors through one-on-one meetings during the virtual event.
Tonix Pharmaceuticals announced the publication of Phase 1 clinical data for TNX-1500, a novel Fc-modified anti-CD40L monoclonal antibody designed to prevent organ transplant rejection and treat autoimmune diseases. The study demonstrated favorable safety, tolerability, and pharmacodynamics in healthy adults, supporting the planned Phase 2 investig…
Kymera Therapeutics, a clinical-stage biotech company specializing in oral small molecule degraders for immunological diseases, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026. The event highlights Kymera's progress in pioneering targeted protein degradation as a novel therapeutic approach.
Lantronix Inc., a provider of Edge AI and Industrial IoT solutions, announced its preliminary addition to the Russell 3000 Index as part of the 2026 Russell indexes reconstitution. This inclusion is reflective of the company's strategic repositioning towards higher-growth and higher-value markets and is expected to enhance its visibility to institu…
BioCryst Pharmaceuticals announces seven abstracts from its hereditary angioedema (HAE) portfolio to be presented at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting. The data focus on ORLADEYO (berotralstat), the first oral prophylactic therapy for HAE, and navenibart, an investigational monoclonal antibody for attack pr…
Korro Bio, a biopharmaceutical company specializing in RNA editing genetic medicines via its OPERA platform, announced CEO Ram Aiyar will present at the 2026 Jefferies Global Healthcare Conference. The presentation highlights Korro's innovative approach to developing treatments for rare and prevalent diseases by precisely editing RNA to enhance the…
